SCHEMBL486108

SCHEMBL486108

CCNc1nc(-c2ccc(NC(=O)NCc3ccc(NC)nc3)c(F)c2)ccc1C(=O)NCCN1CCCCC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 2/20 0.41
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
KCNH2 Q12809 3/20 0.38
CHRNA7 P36544 1/20 0.38
TRPV1 Q8NER1 2/20 0.37
EPHX2 P34913 2/20 0.37
NAMPT P43490 2/20 0.37
CCNT1 O60563 1/20 0.37
CCNA2 P20248 1/20 0.37
CDK2 P24941 1/20 0.37
CDK9 P50750 1/20 0.37
KDM5B Q9UGL1 1/20 0.37
BDKRB1 P46663 1/20 0.37
MET P08581 2/20 0.36
MAP4K4 O95819 1/20 0.36
ADRA2A P08913 1/20 0.36
ADRA2B P18089 1/20 0.36
HTR4 Q13639 1/20 0.36
ADORA2A P29274 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL486437 0.92 TRPV1 (0.41) IKBKBMEN1KMT2AKCNH2CHRNA7
SCHEMBL485908 0.92 PIK3CA (0.41) IKBKBMEN1KMT2AKCNH2CHRNA7
SCHEMBL485903 0.92 PIK3CA (0.41) IKBKBMEN1KMT2AKCNH2CHRNA7
SCHEMBL485853 0.91 PIK3CA (0.41) IKBKBMEN1KMT2AKCNH2CHRNA7
SCHEMBL486214 0.91 MEN1 (0.38) IKBKBMEN1KMT2AKCNH2CHRNA7
SCHEMBL485950 0.90 NAMPT (0.45) IKBKBMEN1KMT2AKCNH2CHRNA7
SCHEMBL486093 0.90 PIK3CA (0.39) IKBKBMEN1KMT2AKCNH2CHRNA7
SCHEMBL3055634 0.89 NAMPT (0.47) MEN1KMT2AKCNH2CHRNA7EPHX2
SCHEMBL486210 0.88 NAMPT (0.51) MEN1KMT2AKCNH2CHRNA7TRPV1
SCHEMBL486031 0.88 MAP4K4 (0.40) IKBKBMEN1KMT2AKCNH2CHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120053170-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS SANOFI (FR) 2012-03-01 US claimed
EP-2411368-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS SANOFI (FR) 2012-02-01 EP claimed
WO-2010109122-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS SANOFI-AVENTIS (FR) 2010-09-30 WO claimed
US-20120053170-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS SANOFI (FR) 2012-03-01 US disclosed
EP-2411368-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS SANOFI (FR) 2012-02-01 EP disclosed
WO-2010109122-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS SANOFI-AVENTIS (FR) 2010-09-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053170-A1 NICOTINAMIDE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF AS ANTICANCER DRUGS NAMPT, NNT, NQO1 IKBKB 1343/4885MEN1 560/4885KMT2A 2289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.